English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduVarious specialists from Rutgers Cancer Institute of New Jersey are available for comment on colorectal cancer topics during the month of March to highlight colorectal cancer awareness month.
Tag: RWJBarnabas Health
Shedding light on the Forgotten Cancer
Rutgers Cancer Institute expert sheds light on sarcoma for rare disease day.
Negligible Detection of SARS-CoV2 found in Environmental Surface Testing of Hematology/Oncology Inpatient and Outpatient Settings
Researchers from Rutgers Cancer Institute of New Jersey evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility. The study, published in Cancer, revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor.
Exploring Impact of Surgery Delays for Clinical Renal Cell Carcinoma Patients during the COVID-19 Pandemic
During the peak of the COVID-19 pandemic, several elective surgeries for renal cell carcinoma, the most common type of kidney cancer, were delayed with unknown impact on outcomes for patients. Researchers at Rutgers Cancer Institute of New Jersey explored the impact of surgery delays for these patients throughout the United States by utilizing the National Cancer Database to explore outcomes of patients who underwent surgery up to and after three months post diagnosis.
Gallbladder and Bile Ducts: Small Organs with Big Responsibilities
Gallbladder cancer and bile duct cancers are rare, which is why it is important to learn the signs and symptoms of these diseases and help spread awareness. Rutgers Cancer Institute expert highlights these types of cancers for Gallbladder and Bile duct cancer awareness month.
Gynecologic Oncology Leader Named at New Jersey’s Only NCI-designated Comprehensive Cancer Center
Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital (RWJUH), a RWJBarnabas Health facility, have named James K. Aikins, Jr., MD, FACOG, FACS chief of gynecologic oncology at Rutgers Cancer Institute and chief of gynecologic oncology services at RWJUH, New Jersey’s largest academic medical center.
Our Role in Beating Cancer Together in New Jersey and Beyond
This year’s theme for World Cancer Day 2021 — “Together, all our actions matter” — calls for individuals to reflect on the idea that collaboration and collective action make us stronger in the fight against cancer and spreads the powerful message that we all have a role to play in reducing the global impact of the disease. At Rutgers Cancer Institute of New Jersey in partnership with RWJBaranabas Health, experts are always working toward the goal of helping individuals fight cancer through onsite research, clinical trials and collaborations with teams locally and across the globe. Learn more about how.
First Patient Recently Treated with New Non-Surgical Therapy for Urothelial Cancer at Rutgers Cancer Institute
Upper tract urothelial cancer (UTUC) is a subset of urothelial cancer that is found in the renal pelvis or the ureter, part of the genitourinary tract. Surgery has remained the mainstay of treatment for this type of cancer, until last year, when the U.S. Food and Drug Administration (FDA) approved mitomycin gel as the first non-surgical therapy option to treat this type of cancer. Rutgers Cancer Institute of New Jersey has recently treated its first UTUC patient with this new therapy.
Environmental Surface Testing in Inpatient and Outpatient Hematology/Oncology Settings Shows Negligible Detection of SARS-CoV2
Researchers from Rutgers Cancer Institute of New Jersey evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility. The study revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor.
Rutgers, RWJBarnabas Health Host Global Neurosurgery Symposium
At 3 a.m. in early September, when most people were still in their beds, more than 400 viewers in China were logged in to a special broadcast, translated in Chinese, focused on neuro-tech and global neurosurgery issues. They were among the thousands of neurosurgeons, residents, medical students and other professionals who tuned in each day to a massive, three-day Global Neurosurgery symposium in September, “Global Neurosurgery: Ask Not for Whom the Bell Tolls.”
What Does it Mean to be An NCI-Designated Comprehensive Cancer Center?
Rutgers Cancer Institute is a National Cancer Institute-designated Comprehensive Cancer Center, a designation reserved for those cancer centers who meet the highest of standards in research, treatment, prevention and education. Rutgers Cancer Institute expert explains why this distinction sets Rutgers Cancer Institute and RWJBarnabas Health apart.
Surgery Milestone Reached for Rutgers Cancer Institute Urologic Oncology Leader at Robert Wood Johnson University Hospital
Rutgers Cancer Institute of New Jersey Urologic Oncology chief marks a major milestone in completing his 2,000th robotic prostatectomy at Robert Wood Johnson University Hospital, an RWJBarnabas Health facility and one of the few hospitals in the state designated to teach surgeons about this technique.
New Rutgers Saliva Test for Coronavirus Gets FDA Approval
The FDA has granted emergency use authorization (EUA) to Rutgers’ RUCDR Infinite Biologics and its collaborators for a new collection approach that utilizes saliva as the primary test biomaterial for the SARS-CoV-2 coronavirus, the first such approval granted by the federal agency. The new saliva collection method, which RUCDR developed in partnership with Spectrum Solutions and Accurate Diagnostic Labs (ADL), will allow for broader population screening than the current method of nose and throat swabs.